Immix Biopharma Stock Discussion

$Immix Biopharma (IMMX.US)$ Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
GlobeNewswire· 
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy
Data will be presented on Monday, December 9, 2024 at 4:00 PM PT

$Immix Biopharma (IMMX.US)$
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma (NASDAQ: IMMX) has expanded its U.S. clinical trial sites for the NEXICART-2 study, evaluating CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients. New sites include Cleveland Clinic, UC Davis, and Sutter Health, joining lead site Memorial Sloan Kettering Cancer Center. This expansion aims to increase patient access and enrollment opportunit...

$Immix Biopharma (IMMX.US)$
Immix Biopharma (Nasdaq: IMMX) has been awarded an $8 million CLIN2 grantfrom the California Institute for Regenerative Medicine (CIRM) to support the clinical development of NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. The funding will be used for the NEXICART-2 U.S. clinical trial, which aims to evaluate the...

$Immix Biopharma (IMMX.US)$ Immix Biopharma Inc - Data From Ex-US Clinical Trial Reported at Asgct 2024 Showed a 92% Overall Response Rate

$Immix Biopharma (IMMX.US)$
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

$Immix Biopharma (IMMX.US)$
NEWS
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma, Inc. has been granted European Orphan Drug Designation for NXC-201 in the treatment of multiple myeloma, providing 10 years of market exclusivity, access to centralized authorization procedure, and reduced fees for various applications. The Company aims to address unmet medical needs in frail patients with relapsed/refractory multiple myeloma, with poten...

$Immix Biopharma (IMMX.US)$ Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
MT Newswires· 1 min ago
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation visits at US testing locations this month and May.
The open-label, phase 1b dose-expansion trial is expected to enroll around 40 patients with adequate cardia...